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Abstract
Objective Eliglustat is an investigational oral substrate reduc-
tion therapy for Gaucher disease type 1 (GD1). Its skeletal
effects were evaluated by prospective monitoring of bone
mineral density (BMD), fractures, marrow infiltration
by Gaucher cells, focal bone lesions, and infarcts during
an open-label, multi-site, single-arm phase 2 trial
(NCT00358150).
Materials and methods Institutional review board approval
and patient informed consent were obtained. Eliglustat (50
or 100 mg) was self-administered by mouth twice daily; 19
patients completed 4 years of treatment. All were skeletally
mature (age range, 18–55 years). DXA and MRI assessments
were conducted at baseline and annually thereafter. X-rays
were obtained annually until month 24, and then every other
year.
Results Lumbar spine BMD increased significantly (p=0.02;
n=15) by a mean (SD) of 9.9 % (14.2%) from baseline to year
4; corresponding T-scores increased significantly (p=0.01)
from a mean (SD) of −1.6 (1.1) to −0.9 (1.3). Mean femur
T-score remained normal through 4 years. Femur MRI
showed that 10/18 (56 %) patients had decreased Gaucher cell
infiltration compared to baseline; one patient with early im-
provement had transient worsening at year 4. There were no
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lumbar spine or femoral fractures and no reported bone crises
during the study. At baseline, 8/19 (42 %) patients had focal
bone lesions, which remained stable, and 7/19 (37 %) patients
had bone infarctions, which improved in one patient by year 2.
At year 4, one new asymptomatic, indeterminate bone lesion
was discovered that subsequently resolved.
Conclusions Eliglustat may be a therapeutic option for
treating the skeletal manifestations of GD1.
Keywords Gaucher disease type 1 . Bone disease . Drug
therapy . Targetedmolecular therapy .Magnetic resonance
imaging . Dual-energyX-ray absorptiometry
Introduction
Skeletal complications are a major cause of morbidity in
patients with Gaucher disease type 1 (GD1) [1–3]. In GD1,
a genetic deficiency of acid β-glucosidase impairs the catab-
olism of glucosylceramide, resulting in intracellular, particu-
larly intralysosomal, glycolipid accumulation [4]. Enlarged,
lipid-laden macrophages known as “Gaucher cells” are ob-
served in most tissues, but heavy infiltrations occur in spleen,
liver, and bone marrow, giving rise to visceromegaly, cytope-
nia, and diverse skeletal lesions associated with mineral loss,
ischemia, and marrow packing [5, 6].
Imaging of the skeleton provides a means of evaluating
GD1 severity and monitoring responsiveness to treatment. On
magnetic resonance (MR) imaging, areas of reduced bone
marrow signal intensity (“dark marrow”) occur in T1-
weighted sequences. Progressive accumulation of Gaucher
cells displaces normal adipocytes from the marrow compart-
ment [1, 7, 8], leading to abnormal quantities and distribution
of “dark marrow.” This process begins in the axial skeleton
and progresses to the appendicular skeleton, advancing in the
lower extremity in a predictable sequence over time [1]. Focal
collections of Gaucher cells may result in lytic lesions. The
mechanistic link between marrow infiltration and the devel-
opment of bony complications is not clear, but extensive
Gaucher cell infiltration is associated with osteopenia, bone
infarctions, avascular necrosis, lytic lesions, and pathological
fractures [1, 5, 9]. Chronic bone pain and acute bone crises
also often accompany skeletal disease in GD1 patients.
Treatment of GD1 with enzyme replacement therapy
(ERT) has been available since 1991. Enzyme replacement
enhances the body’s ability to metabolize the glycolipid. It is
effective, but costly, difficult to produce, and requires intrave-
nous infusion. In 2003, miglustat (Zavesca, Actelion,
Allschwil, Switzerland), a substrate reduction therapy (SRT),
became available for GD1 [10–12], but due to its safety and
tolerability profile, was approved only for patients for whom
ERT is not an option. SRT uses daily regimens of orally
administered, small-molecule inhibitors of glucosylceramide
synthesis to decrease the substrate burden. ERT has been
shown to improve or stabilize bone disease in many patients,
particularly when treatment is initiated before irreversible
pathological changes ensue [8, 13, 14]. The data for miglustat
are more limited [15]. An alternative novel SRT, eliglustat, is
currently in clinical development as a treatment for adults with
GD1. Two-year and 4-year results of an ongoing phase 2
clinical trial have demonstrated a good safety and tolerability
profile, statistically significant improvements in platelet count
and hemoglobin level, decreases in spleen volume and liver
volume, and increases in lumbar spine bone mineral density
and decreased or stabilized bone marrow infiltration by
Gaucher cells [16–18]. Here we report specifically on skeletal
responsiveness to eliglustat after 4 years of eliglustat treatment
in this phase 2 trial.
Materials and methods
Study design
The phase 2 trial was a multi-site, open-label, single-arm study
sponsored by Genzyme, a Sanofi company, and registered as
NCT00358150 at www.clinicaltrials.gov. The Ethics
Committee or Institutional Review Board at each site
approved the protocol. Patients provided written informed
consent in accordance with the Declaration of Helsinki.
Patient privacy was maintained in compliance with the
Health Insurance Portability and Accountability Act. The
main inclusion criteria were a diagnosis of GD1 confirmed
by deficient acid β-glucosidase activity and Gaucher geno-
type, age 18 to 65 years, the presence of splenomegaly with
anemia, and/or thrombocytopenia [16–18]. Patients could not
have received ERT, miglustat, or corticosteroids within the
previous year or bisphosphonates within the previous
3 months. The bone-related exclusion criteria were any new
pathological bone involvement or bone crises in the previous
year.
Of 26 patients enrolled, six discontinued before or at year
1, and one patient discontinued at year 2 [16, 17]. The reasons
for patient discontinuation included asymptomatic non-
sustained ventricular tachycardia (n=2), pregnancy (n=3),
administrative withdrawal (n=1), and bone lesion (n=1).
The patient with the bone lesion was withdrawn after the first
year because of worsening osteonecrosis of the femoral head,
which was asymptomatic and was detected retrospectively on
screening images.
The remaining 19 patients completed 4 years of treatment.
Eliglustat capsules (50 or 100 mg) were self-administered
twice daily; dose selection was based on day-10 plasma drug
concentrations. Spleen volume, liver volume, platelet counts,
and hemoglobin values were determined as previously de-
scribed [14, 15]. Patients were instructed to return any unused
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medication at each study visit to monitor compliance based on
number of returned capsules. Only patients with compliance
rates ≥80 % were included for statistical analysis in the study.
Bone disease assessments
MR and dual-energy X-ray absorptiometry (DXA) images
were obtained at study sites during screening and every
12 months during treatment. Plain radiography (X-ray) was
done annually until year 2, and then every other year. All
images were evaluated by two central reviewers who com-
pared each result to the previous result to assess changes over
time (“better,” “worse,” or “the same”) and were not blinded
to patients or timepoints [19]. Images were assessed for qual-
ity and comparable anatomical sites at all time points and
reviewer consensus was reported. Coronal spin-echo T1-
and T2-weighted MR images of both femurs were obtained
for assessment of focal marrow lesions, infarcts, and dark
marrow.Marrow infiltration, or “dark marrow,”was evaluated
on MR images using a modification of the Rosenthal method
in which 11 anatomical zones in the lower extremity are
numbered according to the sequence in which Gaucher cells
infiltrate, displacing normal fatty marrow [1]. Because MR
images were only obtained of the femur in this study, analysis
was restricted to six zones (see Fig. 1). The presence of dark
marrow on MR was visually assessed in each zone and was
designated as not present, present, unchanged, decreased, or
increased. DXA images of the lumbar spine and femur were
obtained for measurement of bone mineral density (BMD)
using Hologic or Lunar scanners. Data were excluded from
analyses for four patients whose DXA examinations were not
performed on equipment from the same manufacturer at all
assessments. DXA results were expressed as percent change
in BMD from baseline (g/cm2) and as T- and Z-scores [20].
Anterior-posterior radiographs of both femurs and lateral
views of the thoracic and lumbar spine were reviewed for
the presence of infarcts, lytic lesions, fractures, and
osteonecrosis of the femoral head and condyles. Cortical
thickness measurements of the mid-femoral diaphyses were
made to the nearest 0.5 mm using a transparent ruler. Patient
self-assessments of bone pain, bone crises, and mobility were
documented at least every 6 months.
Statistical analyses
To evaluate differences between baseline and year 4, changes
or percent changes from baseline were analyzed using a paired
t test orWilcoxon signed-rank test, as appropriate. To evaluate
associations between the change in BMDT-score and changes
in other clinical parameters, Pearson’s correlation coefficients
were calculated. A p value of 0.05 was considered statistically
significant.
Results
For the 19 study patients, the median age at initiation of
treatment was 31.4 years. All patients were skeletally mature
(age range, 18.6–55.7 years). The extent of splenomegaly,
cytopenia, and skeletal defects at baseline was consistent with
a moderate-to-severe stage of GD1 (Table 1).
As expected, at least some dark marrow was present at
baseline in the femurs of nearly all patients (18/19, 95 %).
There was dark marrow in all six zones in five patients and in
at least three zones in the other 13 patients. The
intertrochanteric region, shaft, and distal metaphysis were
the most commonly affected zones. During 4 years of
eliglustat treatment, 10/18 (56 %) patients showed improve-
ment in one to six zones, while the other eight (44 %) patients
remained stable. At year 4, one patient exhibited worsening
within one of six zones that had previously improved; how-
ever, this patient resumed improvement in dark marrow 1 year
later. The patients who responded with dark marrow improve-
ments tended to be male and to have more zones with marrow
involvement, larger spleen volumes, and lower hemoglobin
levels at baseline. The dark marrow responders also showed
greater improvements in spleen volume, hemoglobin levels,
and platelet counts at year 4 than non-responders (Table 2).
Figure 1 shows that marrow improvements were apparent
by the first year and continued through the fourth year of
treatment. As expected, based upon previous studies, im-
provements in marrow involvement were most frequent in
those sites tending to be affected later in the course of the
disease (the greater trochanter and the condyles). Figure 2
(top) presents pre-treatment and year-4 images from a 55-
year-old female with dark marrow present in all six femoral
zones at baseline. After 2 years of treatment, dark marrow
resolved in the greater trochanter and condyles and decreased
in the other four zones. Figure 2 (bottom) presents images
Fig. 1 Improvements in femur dark marrow during 4 years of eliglustat
treatment. The six zones of the femur are numbered according to the
original method [1]
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from a 30-year-old male with baseline involvement of four
zones; after 4 years of treatment, dark marrow resolved in the
shaft, distal metaphysis and femoral head, but not in the
intertrochanteric region.
Lumbar spine BMD (g/cm2) increased significantly (p=
0.02) from baseline to year 4 by a mean (SD) of 9.9 %
(14.2 %) in the 15 patients with data. This increase in mean
(SD) BMD from 0.99 (0.15) to 1.09 (0.19) g/cm2
corresponded to an increase in mean (SD) T-score from −1.6
(1.1) (osteopenia) to −0.9 (1.3) (normal), and to an increase in
mean (SD) Z-score from −1.17 (0.9) to −0.48 (1.1). Figure 3
displays baseline and year-4 lumbar spine T-scores for each
patient and demonstrates that improvements were observed
across both gender and age. Excluded from the BMD analysis
were two patients assessed with different scanner types at
baseline and follow-up, a patient with local bone abnormali-
ties at screening that precluded BMDmeasurements, and a 40-
year-old male with osteoporosis who was re-instated on
Table 1 Demographics and
baseline characteristics
*n=19 for all parameters, except
where noted
MN multiples of normal, assum-
ing normal liver volume is 2.5 %
of body weight and normal spleen
volume is 0.2 % of body weight



















Parameter* Mean (SD) Median Min-Max
Age at treatment, years 33.6 (12.5) 31.4 18.6–55.7
Age at diagnosis, years (n=18) 24 (13) 22.95 5–52
Number of femur zones with dark marrow (n=18) 4 (2) 4.5 0–6
Lumbar spine bone mineral density, T-score (n=15) −1.6 (1.06) −1.7 −3.1–0.6
Hemoglobin, g/dl 11.3 (1.54) 11.75 8.8–14.6
Platelet count (×1,000/μl) 68.7 (21.16) 66.5 39–105.5
Spleen volume, MN (n=18) 17.3 (9.53) 13.52 10.45–49.16
Liver volume, MN (n=18) 1.7 (0.42) 1.59 1.11–2.47
Table 2 Comparison of patients with and without improvement in dark marrow during 4 years of eliglustat treatment*
Patients with improvement Patients without improvement p value
n (%) 10 (56 %) 8 (44 %)
Age at baseline (years) 31 (18, 55) 31 (19, 53) 0.7557
Ratio of males to females 60:40 25:75 0.1880
Femoral zones with dark marrow
Baseline (n) 5 (3, 6) 3 (3, 6)
Change from baseline to 4 years (n) −3 (−5, −1) 0 (0, 0) 0.0002
Spleen volume
Baseline (MN) 17.0 (10.5, 49.2) 12.8 (10.8, 14.6)
Change from baseline to 4 years (MN) −11.2 (−30.8, −5.5) −7.5 (−10.6, −5.6) 0.1002
Hemoglobin
Baseline (g/dl) 10.9 (8.9, 14.6) 11.9 (8.8, 12.5)
Change from baseline to 4 years (g/dl) 3.1 (0.4, 4.6) 1.4 (0, 2.4) 0.0329
Platelets
Baseline (×1,000/μl) 62.5 (39.0, 105.5) 66.7 (47.0, 95.0)
Change from baseline to 4 years (×1,000/μl) 65.5 (6.5, 212.0) 31.5 (4.0, 99.5) 0.2133
*Data are presented as median (minimum, maximum) for all parameters except the ratio of males to females. Spleen volume inmultiples of normal (MN)
is normalized to body weight, assuming normal spleen volume (ml) is 0.2 % of body weight
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bisphosphonate therapy following a decrease in lumbar spine
T-score from −2.9 at baseline to −3.0 at year 1. For 13 patients
with BMD data for the femur, the mean T-score increased
from −0.04 (0.9) at baseline to 0.13 (1.0) at year 4; the mean
Z-score increased from 0.27 (0.7) at baseline to 0.48 (0.8) at
year 4. Cortical thickness of the mid-femoral diaphyses did
not change from baseline in all 12 patients with data.
No existing (prevalent) fractures or new (incident) fractures
were detected in the spine or femurs of any patient at baseline
or during 4 years of eliglustat treatment. Thirteen focal bone
lesions were observed in the femurs of 8/19 (42 %) patients at
baseline. These pre-existing lesions, located in the diaphysis
(n=7), proximal metaphysis (n=3), distal metaphysis (n=2),
and condyles (n=1), remained stable during treatment, and no
new lesions developed in any patient. Bone infarctions were
present in 7/19 (37 %) patients at baseline, with a total of 12
infarctions detected in the diaphysis (n=6), distal metaphysis
(n=2), femoral head (n=2), intertrochanteric region (n=1),
and condyles (n=1). After 2 years of treatment, two (of four)
Fig. 2 Dark marrow improvement in two patients after 4 years of
eliglustat therapy. Top Coronal T1-weighted MR images of the proximal
right femur of a 55-year-old female patient at baseline (a) and at
48 months (b) demonstrate decreased but persistent dark marrow in the
femoral head epiphysis, greater trochanteric apophysis, and
intertrochanteric region of the proximal femur. Dark marrow has also
largely disappeared from the proximal femoral diaphysis. Coronal T1-
weighted MR images of the distal left femur at baseline (c) and at
36 months (d) demonstrate substantially decreased dark marrow in the
distal femoral diaphysis and metaphysis. Bottom Coronal T1-weighted
MR images of the proximal right femur of a 30-year-old male patient at
baseline (e) and at 48 months (f) demonstrate decreased dark marrow in
the intertrochanteric region and proximal diaphysis of the femur. Coronal
T1-weighted MR images of the distal right femur at baseline (g) and at
48 months (h) in the same patient demonstrate complete resolution of
dark marrow in the distal femoral diaphysis and metaphysis with residual
normal fatty marrow
Fig. 3 Changes in lumbar spine bone mineral density with eliglustat
treatment. Each point represents the T-score for a given patient, with age
at treatment initiation shown adjacent to the symbol
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infarctions improved in a 24-year-old patient. All other pre-
existing infarctions remained stable.
A few instances did not fit the predominant pattern of
statistically significant improvement and are of unclear signif-
icance. A new asymptomatic indeterminate bone lesion and
some worsening of dark marrow were observed at year 4 in
the distal femoral metaphysis of a 55-year-old female (Fig. 2,
top). However, Fig. 4 shows that this lesion was not present
1 year later, and dark marrow at that location continued to
improve beyond the level seen after 3 years of treatment. An
asymptomatic infarction was also detected in the femoral
condyle of a 49-year-old male patient, but it is not known if
the lesion was present at baseline because earlier images did
not include that anatomical site. During the 4-year period,
patient self-assessments indicated that mobility was not re-
stricted before or during treatment for any patient, and no
patient experienced a clinically significant change in bone
pain. No new bone crises were reported.
Discussion
Treatment with eliglustat resulted in improvement in bone
marrow infiltration and lumbar spine BMD that was sustained
for 4 years in the majority of patients. Unlike ERT, in which
enzyme is generally infused every 2 weeks to enhance catab-
olism of glucosylceramide, eliglustat was administered twice
daily by mouth to reduce de novo synthesis of
glucosylceramide. Skeletal responses induced by eliglustat
were qualitatively similar to those reported for ERT with
human placental and recombinant human enzyme prepara-
tions (alglucerase and imiglucerase, respectively, Genzyme,
a Sanofi company) [21]. For the 4-year cohort, eliglustat
treatment resulted in marrow improvements in 28 % of
patients at 1 year and 56 % by the fourth year. This
pattern is similar to imiglucerase, in which marrow
improvements occur within the first year in a small
proportion of patients and the proportion increases with
prolonged treatment, although up to 30 % of patients remain
unresponsive [1, 22, 23].
Marrow infiltration, or “dark marrow,” was evaluated by
MRI of both femurs. With treatment, the highest percentage of
darkmarrow reductions occurred in zones expected to bemost
recently infiltrated, the condyles and greater trochanter,
whereas relatively few reductions were observed in the early
infiltrated intertrochanteric region. Patients with marrow im-
provement tended to have more extensive marrow involve-
ment, more severe splenomegaly, and lower hemoglobin
levels at baseline than patients who did not show improve-
ment (Table 2). Infiltration of vertebral marrow has previously
been associated with splenomegaly [19]. Although these may
be unrelated markers of disease severity, it is possible that
marrow infiltration is exacerbated by splenomegaly, as
cytopenia due to hypersplenism may promote reconversion
of yellow to hematopoietic marrow. Marrow responders also
tended to exhibit greater improvements in spleen size and
hematologic measures with treatment, although this correla-
tion was only statistically significant for hemoglobin level,
perhaps due to the small sample size (Table 2). Restoration of
yellow marrow in bone could reflect the combined effect of
eliglustat on Gaucher cell populations in the spleen (reducing
hypersplenism) and bone marrow (restoring function to nor-
mal sites of hematopoiesis). This phase 2 study enrolled adult
GD1 patients selected on the basis of an enlarged spleen
(volume >10 MN) and the presence of either mild-to-
moderate anemia or mild-to-severe thrombocytopenia, or
both. Retrospective analyses of patients on ERT with imiglu-
cerase have not consistently shown a correlation between
marrow response and improvements in visceral and hemato-
logic parameters, but variability in age of patients, time on
treatment, spleen status, and baseline disease severity could
account for these discrepancies [19, 23, 24].
Improvement in bone density occurred earlier than detect-
able marrow improvement. Eliglustat treatment produced sub-
stantial BMD gains in the first year, which were furthered or
maintained through the fourth year. An increase in BMD was
reported at 6 months for miglustat [15]. The authors of that
study postulated that a small molecule may distribute to bony
compartments that are less accessible to therapeutic enzymes.
These observations suggest that the mineral component of the
skeletonmay show a more rapid response to SRT than to ERT,
recognizing that the rate and magnitude of BMD responses to
ERT (imiglucerase) depend on many factors, including the
dose, BMD status, and age at which enzyme infusions are
initiated [8, 13, 14].
Fig. 4 Resolution of indeterminate lesion and continued dark marrow
improvement in one patient. Coronal T1-weighted MR images of the
distal right femur of a 55-year-old female patient at 36 months (a) and
48 months (b) demonstrate an interval increase in dark marrow in the
distal femoral diaphysis and metaphysis with a new indeterminate
metaphyseal bone lesion at 48 months. At 60 months (c), the bone lesion
resolved and dark marrow continued to improve, even as compared to
36 months, with near-complete resolution of dark marrow in the distal
femoral diaphysis and metaphysis
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Of 15 patients with data for lumbar spine BMD, 12 were
osteopenic or osteoporotic at baseline, and some T-score im-
provement was seen in all but three patients by year 4. T-score
changes did not correlate with marrow improvement (r=
−0.29; p=0.29), but did correlate with changes in platelet
counts (r=0.66; p=0.01) and spleen volume (r=−0.53; p=
0.04). The lack of association between marrow involvement
and bone density has been previously reported [7] and has
suggested that cell types other than the Gaucher macrophage
may play a role in GD1-associated osteopenia [25–27]. The
BMD response to eliglustat could involve direct effects on
osteoblasts, osteoclasts, and/or their precursors, as eliglustat is
widely biodistributed [17, 28, 29]. The apparent increase in
bone density seen on DXA may also reflect changes in the
marrow composition. Additional data will be required to see if
the less reactive cortical bone also demonstrates increasing
density over time. The correlation of BMD improvement with
platelet recovery or spleen volume reduction should not be
assumed to imply causality. Eliglustat produced substantial
improvements in all measures of disease in several patients.
The largest BMD increase after 4 years of treatment was seen
in an 18-year-old male patient whose lumbar spine T-score
rose from osteoporotic to normal range (from −2.8 to 1.2) with
normalization of the Z-score (−2.2 to 1.0), accompanied by
marrow improvements in three of six involved zones and
recoveries in platelets (from 70 to 282 × 1,000/μl), hemoglo-
bin (from 11.9 to 15.1 g/dl), and spleen size (from 28.5 to 2.5
multiples of normal [MN]). It is possible that increases in
BMD may be due to generally improved health status and
activity level. A few patients with abnormal baseline BMD
did not gain skeletal mass, but did exhibit other treatment
benefits. A 31-year-old male patient whose lumbar spine T-
and Z-scores both decreased from −2.3 to−2.7 had improve-
ments in platelets (103 to 161 × 1,000/μl), hemoglobin (12.8
to 14.8 g/dl), spleen size (10.5 to 4.2 MN), and dark marrow
(see Fig. 2 bottom). It is not clear why some patients fail to
gain bone mass, but many factors other than those associated
with GD1 may influence bone formation and could mask or
limit the effect of treatment. Regardless of etiology, low BMD
is recognized as a strong risk factor for fractures of the spine
and femur in GD1 [30]. There were no new fractures among
our patients.
It has been shown that ERT reduces the incidence of
bone crises and bone pain associated with skeletal le-
sions [13, 31]. The patients who completed 4 years of
treatment did not report any bone crises, and no symp-
tomatic infarctions were identified on imaging. Two pre-
existing infarcts improved in one patient. Although this result
is encouraging, conclusions cannot be drawn about a treat-
ment effect since spontaneous healing of osteonecrosis has
been reported [32].
We do not have an explanation for the asymptomatic
indeterminate lesion that appeared in the distal femoral
metaphysis in one patient. It was accompanied by re-
appearance of dark marrow in the same location (although
not in the other five zones) (Fig. 2, top). The lesion was not
present on images obtained 1 year later, the dark marrow in
this region had resumed its improvement, and all hematologic
and visceral parameters showed continuous improvement
(Fig. 4).
The main limitations of this trial are the small number of
patients, especially given the clinical heterogeneity of GD1;
the uncontrolled study design of this proof-of-concept
phase 2 trial; and the unblinded reviews of the bone
images. However, this trial provides useful and objec-
tive information about the long-term effect of eliglustat
on bone manifestations of Gaucher disease. Additional data
from an ongoing phase 3 randomized, controlled trial in
treatment-naive adults with GD1 (ENGAGE) will provide
further insight into the effect of eliglustat on hematologic,
visceral, and bone parameters.
Conclusions
The results of radiologic assessments of bone suggest that
eliglustat, an investigational oral SRT, may be a therapeutic
option for treating the skeletal manifestations of GD1. An
initial comprehensive radiologic evaluation of GD1 patients
for marrow and osseous complications should form the basis
for monitoring the effects of eliglustat treatment at regular
intervals.
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